Literature DB >> 8929064

Biological variation in urinary excretion of pyridinium crosslinks: recommendations for the optimum specimen.

M Panteghini1, F Pagani.   

Abstract

We assessed the analytical and biological variation of pyridinium crosslinks in early morning, 2 h fasting, and 24 h urine specimens from 14 healthy adults over a 1 month period. The results were expressed both in terms of pyridinoline concentration and pyridinoline/creatinine ratio. The data obtained were used to select the optimum specimen for clinical purposes. We found that: (a) early morning specimens are preferred; (b) results should be expressed as pyridinoline/creatinine ratio; (c) reference intervals should be stratified according to gender; (d) the necessary analytical imprecision (CV < or = 9%), derived from biological variation, is not easily achieved by current methods; (e) the difference between serial results from an individual must be > 50% to be statistically significant; and (f) assessment of risk for osteoporotic fracture by means of the pyridinium crosslink assay would, in a significant number of patients, require analysis of multiple urine specimens.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8929064     DOI: 10.1177/000456329603300105

Source DB:  PubMed          Journal:  Ann Clin Biochem        ISSN: 0004-5632            Impact factor:   2.057


  3 in total

Review 1.  Fast and slow bone losers. Relevance to the management of osteoporosis.

Authors:  S Hough
Journal:  Drugs Aging       Date:  1998       Impact factor: 3.923

2.  A proposal for standardizing urine collections for bone resorption markers measurement.

Authors:  M Zaninotto; D Bernardi; F Ujka; P Bonato; M Plebani
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

3.  Parathyroid hormone and bone marker levels in patients with morbid obesity before and after biliopancreatic diversion.

Authors:  J Moreiro; O Ruiz; G Perez; R Salinas; J R Urgeles; M Riesco; M García-Sanz
Journal:  Obes Surg       Date:  2007-03       Impact factor: 3.479

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.